Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules that utilize mitochondrial uncoupling to enhance fat oxidation and improve cellular metabolism. Their lead candidate, HU6, targets obesity and related cardiometabolic diseases by promoting fat-specific weight loss while preserving muscle mass and improving key metabolic parameters.
Funding
$224M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity and related cardiometabolic diseases, such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD), and type 2 diabetes, are driven by excess fat accumulation. Current weight loss therapies may also reduce lean muscle mass, potentially leading to weight regain and increased cardiovascular risk.
Solution
Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules designed to reduce excess fat and treat a range of cardiometabolic diseases. CMAs safely leverage mitochondrial uncoupling, a natural metabolic process, to promote fat-specific weight loss while preserving muscle mass. By increasing the breakdown of fats and sugars and increasing resting energy expenditure, CMAs improve cellular metabolism and address the underlying cause of cardiometabolic diseases. Rivus' lead CMA candidate, HU6, is currently in clinical development for obesity and associated cardiometabolic diseases.
Target Audience
The primary target audience includes patients with obesity and related cardiometabolic diseases such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes, as well as physicians and healthcare providers treating these conditions.
Features
- Oral, small molecule therapies designed to improve cellular metabolism
- Harnesses mitochondrial uncoupling to increase fat oxidation and energy expenditure
- Promotes fat-specific weight loss while preserving skeletal muscle mass
- Reduces liver and visceral fat
- Improves glycemic control and reduces inflammation
- HU6, a first-in-class CMA, has demonstrated improvements in disease markers of blood pressure, inflammation, and glycemic control in Phase 2 clinical trials
- Pipeline includes additional CMA candidates for preclinical development
- AI/ML classifier model trained on proprietary datasets to identify new CMA candidates